Evaluating drug targets through human loss-of-function genetic variation.

MLA

Minikel, Eric Vallabh, et al. “Evaluating Drug Targets through Human Loss-of-Function Genetic Variation.” Nature, vol. 581, no. 7809, May 2020, pp. 459–64. EBSCOhost, https://doi.org/10.1038/s41586-020-2267-z.

APA

Minikel, E. V., Karczewski, K. J., Martin, H. C., Cummings, B. B., Whiffin, N., Rhodes, D., Alföldi, J., Trembath, R. C., van Heel, D. A., Daly, M. J., Schreiber, S. L., & MacArthur, D. G. (2020). Evaluating drug targets through human loss-of-function genetic variation. Nature, 581(7809), 459–464. https://doi.org/10.1038/s41586-020-2267-z

Chicago

Minikel, Eric Vallabh, Konrad J Karczewski, Hilary C Martin, Beryl B Cummings, Nicola Whiffin, Daniel Rhodes, Jessica Alföldi, et al. 2020. “Evaluating Drug Targets through Human Loss-of-Function Genetic Variation.” Nature 581 (7809): 459–64. doi:10.1038/s41586-020-2267-z.